In fact, the HGF/Met signalling pathway is importantly involved in pathogenesis of pancreatic cancer, and HGF/Met inhibitors are believed to become in near future crucial therapeutics for pancreatic cancer management.28 Importantly, HGF/SF then activates the signalling components, including Ras, that are required for the signal transduction from the c‐Met receptor towards the ERK pathway (Figure 6A). This evidence concerns the gene MET and pancreatic neoplasm.